Jin-Quan Yu | |
|---|---|
余金权 | |
| Born | January 10, 1966 |
| Alma mater | University of Cambridge Ph.D. (1999)
Guangzhou Institute of Chemistry M.Sc. (1990) East China Normal University B.Sc. (1987) |
| Known for | Meta-selective C–H functionalization |
| Scientific career | |
| Fields | Organic Chemistry, Organometallic chemistry, Carbon–hydrogen bond activation, Enantioselective synthesis |
| Institutions | Scripps Research (2007-present)
Brandeis University (2004-2007) University of Cambridge (2003-2004) |
| Doctoral advisor | Jonathan B. Spencer |
| Other academic advisors | E. J. Corey |
| Website | www |
Jin-Quan Yu (simplified Chinese: 余金权; traditional Chinese: 余金權; pinyin: Yú Jīn-quán) is a Chinese-born American chemist. He is the Frank and Bertha Hupp Professor of Chemistry at Scripps Research, where he also holds the Bristol Myers Squibb Endowed Chair in Chemistry.[1][2][3] He is a 2016 recipient of the MacArthur Fellowship,[4] and is a member of the American Academy of Arts and Sciences, American Association for the Advancement of Science, and the Royal Society of Chemistry.[3][5] Yu is a leader in the development of C–H bond activation reactions in organic chemistry, and has reported many C–H activation reactions that could be applicable towards the synthesis of drug molecules and other biologically active compounds. He also co-founded Vividion Therapeutics in 2016 with fellow Scripps chemists Benjamin Cravatt and Phil Baran,[6][7] and is a member of the scientific advisory board of Chemveda Life Sciences.[8]
- ^ Jennewein, Chris (2020-12-08). "McArthur Fellow Jin-Quan Yu Named to Newly-Endowed Chemistry Chair". Times of San Diego. Retrieved 2021-05-22.
- ^ "Yu, Jin-Quan". vivo.scripps.edu. Retrieved 2021-05-22.
- ^ a b "Jin-Quan Yu | Scripps Research". www.scripps.edu. Retrieved 2021-05-22.
- ^ "Jin-Quan Yu". www.macfound.org. Retrieved 2021-05-22.
- ^ "Jin-Quan Yu". American Academy of Arts & Sciences. Retrieved 2021-05-22.
- ^ "Vividion Therapeutics: Creating a New Era in Drug Discovery". Retrieved 2021-05-23.
- ^ Fikes, Bradley J. "Vividion Therapeutics to get $101 million upfront from alliance with Celgene". chicagotribune.com. Retrieved 2021-05-23.
- ^ "Scientific Advisory Board | Chemveda Life Sciences". Retrieved 2021-05-23.